文献速递贫血与红细胞疾病血栓与止血

美国食品药品监督管理局促红细胞生成素刺激剂黑框警告对使用及不良结局的影响

Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
PubMed 文献 · J Clin Oncol · 2017-04-25

该研究利用2004至2009年SEER-Medicare数据,采用双重差分法分析美国食品药品监督管理局促红细胞生成素刺激剂黑框警告对使用和静脉血栓栓塞风险的影响。样本共45,319例患者,干预组为接受化疗的结直肠癌、乳腺癌或肺癌患者,对照组为骨髓增生异常综合征患者。结果显示黑框警告与干预组促红细胞生成素刺激剂使用可能性降低20.2个百分点相关(P < .001),但与住院静脉血栓栓塞风险无显著关联。

要点

  • 黑框警告后,干预组促红细胞生成素刺激剂使用可能性降低20.2个百分点(P < .001)。
  • 黑框警告与住院静脉血栓栓塞风险无显著关联。
  • 警告前两组促红细胞生成素刺激剂使用趋势相似,警告后仅干预组急剧下降。

核心结论

  • 研究表明该黑框警告有效减少了促红细胞生成素刺激剂的使用。
  • 未来研究应检验其他监管药品安全措施(如风险评估与缓解策略倡议)的效果,其有效性仍未知。

研究设计与样本

  • 利用2004至2009年SEER-Medicare数据开展自然实验,采用线性概率模型的双重差分设定进行估计。
  • 干预组为美国食品药品监督管理局黑框警告针对的、接受化疗的结直肠癌、乳腺癌或肺癌的Medicare按服务收费患者;对照组为未被该警告针对的骨髓增生异常综合征患者。
  • 警告前期为2004年1月至2006年9月,警告后期为2007年4月至2009年9月;样本共45,319例独特患者。
  • 两个二分类因变量为促红细胞生成素刺激剂使用和住院静脉血栓栓塞。

主要发现

  • 警告前干预组与对照组的促红细胞生成素刺激剂使用趋势保持相似,警告后仅干预组开始急剧下降。
  • 住院静脉血栓栓塞趋势相对稳定。
  • 回归显示黑框警告与针对癌症的促红细胞生成素刺激剂使用可能性降低20.2个百分点相关(P < .001)。
  • 黑框警告与住院静脉血栓栓塞的可能性无显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose In March 2007, a US Food and Drug Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse events, such as venous thromboembolism (VTE). We evaluated the US Food and Drug Administration's boxed warning of ESAs used to treat chemotherapy-induced anemia because evidence on the effectiveness of boxed warnings remains inconclusive. Patients and Methods Using 2004 to 2009 SEER-Medicare data, we exploited a natural experiment to examine the effects of ESA boxed warnings on utilization and risk of VTE. The intervention group included Medicare fee-for-services patients diagnosed with colorectal, breast, or lung cancers targeted by this warning and undergoing chemotherapy; the control group included patients with myelodysplastic syndromes not targeted by this warning. The period from January 2004 to September 2006 was used as the prewarning period; the period from April 2007 to September 2009 was used as the postwarning period. The two binary dependent variables included ESA use and hospitalized VTE. Linear probability models with a difference-in-differences specification were used for estimation. Results Our sample consisted of 45,319 unique patients between 2004 and 2009. The trends in ESA use remained similar between the intervention and control groups before the warning, but started declining sharply in the intervention group only after the warning. The trends in hospitalized VTE were relatively stable. Regressions showed that the ESA boxed warning was associated with a 20.2-percentage-point reduction ( P < .001) in the likelihood of ESAs being used to treat cancers targeted by the warning, but not significantly associated with the likelihood of hospitalized VTE. Conclusion Our study showed that the warning was effective in reducing ESA utilization. Future studies should examine other regulatory drug safety actions, such as the Risk Evaluation and Mitigation Strategy initiative, whose effectiveness remains unknown.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bian J, Chen B, Hershman DL, et al. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017. PMID: 28441110. doi:10.1200/JCO.2017.72.6273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。